SCHEMBL23001982

SCHEMBL23001982

CC#Cc1cccc(Oc2c(C(=O)OCC)nnn2Cc2ccc(OC)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 7/20 0.47
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
AKR1C3 P42330 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 4/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
RECQL P46063 1/20 0.42
HPGD P15428 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ALOX15 P16050 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
UCHL1 P09936 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28047047 0.90 CYP19A1 (0.50) CYP19A1POLBMAPTRXFP1AKR1C3
SCHEMBL29891535 0.89 AKR1C3 (0.47) POLBMAPTRXFP1AKR1C3HSD17B10
SCHEMBL21296973 0.86 CYP19A1 (0.55) CYP19A1POLBMAPTRXFP1AKR1C3
SCHEMBL23001814 0.86 CYP19A1 (0.47) CYP19A1POLBMAPTRXFP1AKR1C3
SCHEMBL29692354 0.86 CYP19A1 (0.47) CYP19A1POLBMAPTRXFP1AKR1C3
SCHEMBL29692421 0.86 CYP19A1 (0.55) CYP19A1POLBMAPTRXFP1AKR1C3
SCHEMBL22795533 0.85 CYP19A1 (0.57) CYP19A1POLBMAPTRXFP1AKR1C3
SCHEMBL22816535 0.85 CYP19A1 (0.45) CYP19A1POLBMAPTRXFP1AKR1C3
SCHEMBL21296982 0.84 CYP19A1 (0.45) CYP19A1POLBMAPTRXFP1AKR1C3
SCHEMBL18241057 0.84 CYP19A1 (0.45) CYP19A1POLBMAPTRXFP1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2025-06-12 US disclosed
US-12213976-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2025-02-04 US disclosed
CN-114980886-B Compounds and methods for treating oxalate-related diseases 奥沙鲁克斯公司 2024-08-09 CN disclosed
US-20230110495-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2023-04-13 US disclosed
US-11504367-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-11-22 US disclosed
CN-114980886-A Compounds and methods for treating oxalate-related diseases 奥沙鲁克斯公司 2022-08-30 CN disclosed
EP-4017490-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES Oxalurx, Inc. (US) 2022-06-29 EP disclosed
US-20210052586-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2021-02-25 US disclosed
WO-2021035196-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052586-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT CYP19A1 1765/4885POLB 1954/4885MAPT 1574/4885
US-11504367-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, OAT CYP19A1 1765/4885POLB 1954/4885MAPT 1574/4885
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT CYP19A1 1765/4885POLB 1954/4885MAPT 1574/4885
US-20230110495-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT CYP19A1 1765/4885POLB 1954/4885MAPT 1574/4885
US-12213976-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, OAT CYP19A1 1765/4885POLB 1954/4885MAPT 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.